Welcome to our dedicated page for ViewRay news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on ViewRay stock.
ViewRay, Inc. (Nasdaq: VRAY) is a trailblazer in the field of MRI-guided adaptive radiotherapy. The company designs, manufactures, and markets the MRIdian® radiation therapy system, an innovative solution aimed at addressing the key limitations of conventional external-beam radiation therapy technologies. Using cutting-edge MRI-based technology, the MRIdian system provides real-time imaging that precisely distinguishes the targeted tumor from surrounding soft tissue and critical organs during radiation treatment.
One of the standout features of the MRIdian system is its capability to record the level of radiation exposure the tumor receives and adapt the treatment prescription as needed. This adaptive approach enhances the safety and efficacy of radiation therapy, which ViewRay believes will lead to better patient outcomes.
ViewRay has established itself as a visionary in the medical field, dedicated to providing doctors with advanced tools to improve cancer treatment through radiation therapy. The company prides itself on its entrepreneurial spirit and unwavering commitment to innovation and excellence.
Among its recent achievements, ViewRay announced that the VA Oklahoma City Healthcare System has selected the MRIdian system to expand its radiation therapy services. This marks the first cancer center in Oklahoma to offer Veterans access to MRIdian's advanced MRI-guided radiation therapy. The system will enable precision treatment for various cancers, including pancreas, prostate, lung, liver, breast, and oligometastatic disease.
The Veterans Health Administration, the largest integrated healthcare system in America, is actively incorporating MRIdian technology across multiple VA medical centers. This expansion highlights the growing recognition of MRIdian's short-course non-invasive therapy, which promises fewer side effects and improved quality of life for patients.
To date, over 31,000 patients worldwide have been treated using MRIdian systems, with 62 installations in hospitals across the globe. These systems are employed to treat a diverse range of solid tumors and are subjects of numerous ongoing research studies. The MRIdian system has been featured in hundreds of peer-reviewed publications and scientific presentations, underscoring its clinical significance and impact.
For a list of treatment centers utilizing MRIdian technology, visit ViewRay's website.
ViewRay, Inc. (NASDAQ: VRAY) announced the purchase of a MRIdian MRI-Guided Radiation Therapy System by Saitama Medical University International Medical Center for its cancer center in Hidaka-City, Japan. Scheduled for installation in December 2022, the system will enhance personalized treatments for various cancers, including those of the pancreas and prostate. This advanced technology allows for real-time tracking and automated beam gating, facilitating efficient treatment delivery. Saitama aims to participate in international research to further cancer treatment methodologies.
ViewRay, Inc. (Nasdaq: VRAY) will release its first quarter 2022 financial results on August 2, 2022, followed by a conference call at 4:30 p.m. ET. Investors can join via dial-in numbers or listen to a live webcast on the company's investor relations page. A replay will be available online for 14 days, and telephonic replays will be accessible until August 16, 2022. ViewRay specializes in MR-guided radiation therapy systems, particularly the MRIdian system, designed to enhance treatment in radiation oncology.
ViewRay, Inc. (Nasdaq: VRAY) announced that the VA Ann Arbor Healthcare System has selected its MRIdian MRI-guided radiation therapy system to enhance cancer treatment services at the Lieutenant Colonel Charles S. Kettles VA Medical Center. This addition allows the facility to provide advanced radiation therapy for various cancers, enhancing care for veterans in the region. The MRIdian system enables precise treatment by utilizing real-time MRI visualization, improving the safety and effectiveness of radiation therapy. Over 22,000 patients have been treated using MRIdian worldwide.
ViewRay, Inc. (NASDAQ: VRAY) announced that Shin-Matsudo Central General Hospital in Japan has acquired a MRIdian MRI-guided radiation therapy system. This marks the third installation of the MRIdian system in Japan, aimed at addressing a growing cancer patient population in the Toukatsu area. The system will enhance treatment precision for cancers such as pancreas and prostate, utilizing advanced techniques including stereotactic body radiation therapy (SBRT). Patient treatments are expected to commence in early Fall 2023.
ViewRay, Inc. (Nasdaq: VRAY) announces that Henry Ford Health is the first center globally to complete patient treatments using the new MRIdian A3i System. This system enhances clinical workflow by reducing treatment times and enabling advanced brain treatment capabilities. Features include automated contouring and multi-plane tracking, improving treatment precision. Over 21,000 patients have benefited from MRIdian's technology, and 50 systems are operational worldwide. Henry Ford's leadership in MR-guided radiation therapy continues as they pioneer brain treatment with the MRIdian A3i.
ViewRay, Inc. (Nasdaq: VRAY) has released a retrospective study highlighting the effectiveness of its MRIdian system for treating ultracentral and central lung lesions with minimal toxicity. Presented at the ESTRO 2022 conference, the study indicates that MRI-guided stereotactic body radiation therapy (SBRT) resulted in excellent oncologic outcomes in 29 patients, with only one Grade 3 toxicity recorded. This stands in contrast to previous non-MRI studies that reported high toxicity rates. The MRIdian system's real-time tracking and automated beam control enhance treatment precision while minimizing damage to surrounding tissues.
ViewRay, Inc. (Nasdaq: VRAY) celebrates 10 years of pioneering real-time tissue tracking with automatic beam gating. At the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) from May 6-10, 2022, the MRIdian MRI-guided radiation therapy system will showcase nearly 40 presentations on its clinical applications. Key features of the MRIdian A3i will be presented during a symposium on May 7, emphasizing its innovative treatment capabilities. Over 21,000 patients have benefited from MRIdian, which remains the only system offering this technology.
ViewRay, Inc. (Nasdaq: VRAY) reported first-quarter 2022 revenue of approximately $18.9 million, up from $15.5 million in the same quarter of 2021. The company received seven new orders for MRIdian systems totaling $40.9 million, increasing total backlog to $330.9 million. Despite a net loss of $25.8 million or $(0.14) per share, a slight improvement from $26.7 million or $(0.17) per share the previous year, ViewRay has $183.2 million in cash. The company maintains its 2022 revenue guidance of $84 million to $104 million.
ViewRay, Inc. (NASDAQ: VRAY) announced the purchase of its MRIdian MRI-guided radiation therapy system by UCI Health for the new Chao Family Comprehensive Cancer Center, set to open in late 2023. This center is part of a $1.3 billion medical facility being built in Orange County. The MRIdian system offers advanced cancer treatment by providing real-time MR imaging and adaptive therapy, allowing targeted treatment while minimizing damage to healthy tissues. With over 21,000 patients treated using MRIdian, this innovative technology enhances treatment options for complex cases in the region.
ViewRay, Inc. (Nasdaq: VRAY) announced a conference call scheduled for May 5, 2022, at 4:30 p.m. ET to discuss its first-quarter financial results. The call can be accessed domestically at (844) 277-1426 and internationally at (336) 525-7129. A live webcast will be available on the company's investor relations site and will remain accessible for 14 days after the event. ViewRay specializes in innovative MR-guided radiation therapy systems, focusing on advanced radiation oncology.
FAQ
What does ViewRay, Inc. specialize in?
What is the MRIdian® system?
What recent achievement has ViewRay announced?
How many patients have been treated with the MRIdian system?
How many MRIdian systems are currently installed worldwide?
What types of cancer can be treated with MRIdian?
Why is MRIdian considered advanced in radiation therapy?
What are some common side effects of radiation therapy with MRIdian?
Is MRIdian suitable for all patients?
Where can I find more information about MRIdian treatment centers?
